Organon & (OGN) financial statements
Organon & reported revenue of $6.2B in fiscal 2025, down 3.7% a year over 6 years.
Net income was $187M.
Free cash flow was $538M, and the company returned $88M in dividends.
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Organon &'s 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $7.8B | $6.5B | $6.3B | $6.2B | $6.3B | $6.4B | $6.2B |
| Cost of revenue | $2.3B | $2.1B | $2.4B | $2.3B | $2.5B | $2.7B | $2.9B |
| Gross profit | $5.5B | $4.4B | $3.9B | $3.9B | $3.7B | $3.7B | $3.3B |
| Research and development | $220M | $210M | $443M | $471M | $528M | $469M | $366M |
| Selling, general and admin | $1.4B | $1.4B | $1.7B | $1.7B | $1.9B | $1.8B | $1.7B |
| Interest expense | $0 | $0 | $258M | $422M | $527M | $520M | $504M |
| Pre-tax income | $3.7B | $2.8B | $1.5B | $1.1B | $673M | $807M | $425M |
| Income tax | $390M | $496M | $178M | $205M | -$350M | -$57M | $238M |
| Net income | $3.2B | $2.2B | $1.4B | $917M | $1.0B | $864M | $187M |
| EPS (diluted) | $12.69 | $8.52 | $5.31 | $3.59 | $3.99 | $3.33 | $0.72 |
| Diluted shares | 254M | 254M | 254M | 255M | 256M | 259M | 261M |
| Gross margin | 70.8% | 67.6% | 62.2% | 62.8% | 59.8% | 58.0% | 53.3% |
| Net margin | 41.4% | 33.1% | 21.4% | 14.9% | 16.3% | 13.5% | 3.0% |
Balance sheet
Fiscal years, from Organon &'s 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $0 | $12M | $737M | $706M | $693M | $675M | $574M |
| Receivables | — | $1.0B | $1.4B | $1.5B | $1.7B | $1.4B | $1.3B |
| Inventory | — | $913M | $915M | $1.0B | $1.3B | $1.3B | $1.4B |
| Total current assets | — | $3.6B | $3.8B | $3.9B | $4.5B | $4.3B | $4.4B |
| Property, plant and equipment | — | $984M | $973M | $1.0B | $1.2B | $1.2B | $1.3B |
| Goodwill | — | $4.6B | $4.6B | $4.6B | $4.6B | $4.7B | $4.2B |
| Total assets | — | $10.1B | $10.7B | $11.0B | $12.1B | $13.1B | $12.9B |
| Total current liabilities | — | $2.7B | $2.6B | $2.5B | $2.9B | $2.7B | $2.4B |
| Long-term debt | — | $0 | $9.1B | $8.9B | $8.8B | $8.9B | $8.6B |
| Total liabilities | — | $4.6B | $12.2B | $11.8B | $12.1B | $12.6B | $12.1B |
| Shareholders' equity | $7.0B | $5.5B | -$1.5B | -$892M | -$70M | $472M | $752M |
| Net debt | $0 | -$12M | $8.4B | $8.2B | $8.1B | $8.2B | $8.1B |
Cash flow
Fiscal years, from Organon &'s 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.0B | $2.3B | $2.2B | $858M | $799M | $939M | $700M |
| Capital spending | $92M | $255M | $192M | $196M | $251M | $175M | $162M |
| Free cash flow | $2.9B | $2.0B | $2.0B | $662M | $548M | $764M | $538M |
| Stock-based compensation | $41M | $40M | $59M | $75M | $101M | $105M | $77M |
| Dividends paid | $0 | $0 | $145M | $290M | $294M | $297M | $88M |
| Net borrowing | $0 | $0 | $9.4B | -$108M | -$258M | -$11M | -$458M |
| Free cash flow margin | 37.6% | 31.1% | 31.2% | 10.7% | 8.7% | 11.9% | 8.7% |
| Dividends per share | — | — | $0.57 | $1.14 | $1.15 | $1.15 | $0.34 |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for OGN.
Open OGN in InvestinglyQuestions
What was Organon &'s revenue in 2025?
$6.2B in fiscal 2025, from its 10-K filing.
How much free cash flow does Organon & generate?
$538M in fiscal 2025 (operating cash flow minus capital spending).
From Organon &'s annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.